Daclizumab

Grey

Brand Name(s):Zinbryta

Indication:Relapsing Multiple Sclerosis (RMS)

Rationale:3

Considered:Oct-16

Review Date:Oct-23

Comments:
Drug Safety Update
Daclizumab beta: risk of immune-mediated encephalitis – some cases several months after stopping treatment
September 2018
…………………………
Drug Safety Update
Daclizumab: suspension and recall for safety reasons; review patients as soon as possible and start alternative therapy
March 2018
……………………………………
Drug Safety Update
Risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment
Jul-17